Lupus Treatment Report

www.LupusTreatmentReport.com

News

American College of Rheumatology Secures $7M Grant to Address Gaps in Lupus Care and Treatment

https://www.rheumatology.org/About-Us/Newsroom/Press-Releases/ID/1097

American College of Rheumatology Secures $7M Grant to Address Gaps in Lupus Care and Treatment
September 21, 2020

ATLANTA — The American College of Rheumatology (ACR) was recently awarded a $7M grant to reduce inequities in symptom recognition, care and disease management of systemic lupus erythematosus (lupus). The grant, which will be led by the ACR’s Collaborative Initiatives (COIN) department, begins on September 30.

Quercetin is a potential therapeutic drug for lupus nephritis (LN)

https://onlinelibrary.wiley.com/doi/abs/10.1002/ptr.6430

https://www.ncbi.nlm.nih.gov/pubmed/31317585?dopt=Abstract

Quercetin reduces TNF-α-induced mesangial cell proliferation and inhibits PTX3 production: Involvement of NF-κB signaling pathway.

Phytother Res. 2019 Jul 18;:

Authors: Liu Y, Yu C, Ji K, Wang X, Li X, Xie H, Wang Y, Huang Y, Qi D, Fan H

Abstract

Lupus nephritis (LN) is an autoimmune disease caused by systemic lupus erythematosus. Excessive proliferation of mesangial cells is one of the most serious pathological manifestations of LN. In addition, the expression of PTX3 is elevated in the serum of patients with LN. Quercetin has good anti-inflammatory effects and immunomodulatory activities. In this study, the result of MTT indicated that quercetin treatment alleviated the excessive proliferation of mesangial cells. ELISA and immunofluorescence experiments showed that quercetin treatment inhibited the expression of PTX3. Three doses of quercetin (20, 40, and 80 μM) were selected for the experiment. It is noteworthy that the efficacy of quercetin at 80 μM was significantly better than that of other dose groups. And the effect in inhibiting PTX3 expression was comparable with that of the PDTC (80 μM) positive control. Western blot and qRT-PCR analysis revealed that quercetin treatment reduced the expression of nuclear factor-κB p65 and IKKβ, increased the expression of IκBα, and inhibited the expression of PTX3. In conclusion, through inhibiting the activation of nuclear factor-κB signaling pathway, quercetin treatment could reduce the expression of PTX3 and inhibit the excessive proliferation of mesangial cells, suggesting that quercetin is a potential therapeutic drug for LN.

PMID: 31317585 [PubMed – as supplied by publisher]

PubMed:31317585

Chinese Nobel laureate ‘cautiously optimistic’ about progress towards lupus treatment [artemisinin]

https://www.scmp.com/lifestyle/health-wellness/article/3016269/chinese-nobel-laureate-cautiously-optimistic-about

Chinese Nobel laureate ‘cautiously optimistic’ about progress towards lupus treatment

– Tu Youyou won the 2015 Nobel Nobel Prize in Medicine for her discovery of artemisinin, a herbal extract used to treat malaria

– Tu’s team found that artemisinin may also be effective against the autoimmune disease lupus
SCMP

Fifi Tsui

Oasis Li

Published: 5:45pm, 28 Jun, 2019

Aptevo Therapeutics Begins Phase 1 Clinical Trial of APVO210 a Novel Bispecific Antibody for the Treatment of Autoimmune and Inflammatory Diseases

https://pipelinereview.com/index.php/2019032070794/Antibodies/Aptevo-Therapeutics-Begins-Phase-1-Clinical-Trial-of-APVO210-a-Novel-Bispecific-Antibody-for-the-Treatment-of-Autoimmune-and-Inflammatory-Diseases.html

https://www.lupus.org/news/new-treatment-for-autoimmune-inflammatory-diseases-begins-phase-1-trial-in-australia

Aptevo Therapeutics Begins Phase 1 Clinical Trial of APVO210 a Novel Bispecific Antibody for the Treatment of Autoimmune and Inflammatory Diseases

Neovacs to host KOL Meeting to discuss its therapeutic vaccine IFNalpha Kinoid for lupus treatment – February 11th Paris

https://globenewswire.com/news-release/2019/02/05/1710290/0/en/Neovacs-to-host-KOL-Meeting-to-discuss-its-therapeutic-vaccin-IFNalpha-Kinoid-for-lupus-treatment-February-11th-Paris.html

Neovacs to host KOL Meeting to discuss its therapeutic vaccin IFNalpha Kinoid for lupus treatment – February 11th Paris

>>> fixed typo in title (vaccin = french word for vaccine)

Asthma Drug Explored in SLE

https://www.medpagetoday.com/rheumatology/lupus/77416

Asthma Drug Explored in SLE
– Anti-IgE antibody promising as add-on therapy in phase 1b study

Lupus Research Alliance Announces Translational Research Grants to Speed Development of New Treatments

https://www.prnewswire.com/news-releases/lupus-research-alliance-announces-translational-research-grants-to-speed-development-of-new-treatments-300776585.html

Lupus Research Alliance Announces Translational Research Grants to Speed Development of New Treatments

NEW YORK, Jan. 10, 2019 /PRNewswire/ — Can “borrowed” drugs for treating other diseases protect the skin in patients with lupus? Can researchers coax the body to weed out harmful immune cells that drive tissue destruction in lupus? Those are just two of the innovative approaches for lupus therapies recognized by the Lupus Research Alliance with the latest round of its Target Identification in Lupus (TIL) grants. Seven outstanding scientists from across the United States will receive awards worth up to $600,000 for research projects designed to test promising strategies for treating lupus.

Back to top